Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity - Frontiers in Endocrinology Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity - JAMA Internal Medicine Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - New England Journal of Medicine Tirzepatide for Diabetes Improves Glycemic Control After Switch From GLP-1RA - Endocrinology Advisor Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - Diabetes, Obesity and Metabolism
[DOI] [PMC free article] [PubMed] [Google Scholar] 70.Bost M, Houdart S, Oberli M, Kalonji E, Huneau JF, Margaritis I
Researchers continue to investigate how NNMT inhibition affects intracellular signaling, energy utilization, and the complex biochemical pathways involved in maintaining cellular homeostasis
Elevated circulating IGF-1 led to an activation of the IGF-1PI3KAkt signalling pathway, causing augmented mTOR phosphorylation and higher phospho-FoxO/total FoxO ratio in skeletal muscle of LC supplemented rats [33]
[DOI] [PMC free article] [PubMed] [Google Scholar] 72.Ratnasari N., Walters M., Tsopmo A